Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
Date:10/30/2008

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2008. These results are expected to be disclosed on Thursday, November 6, 2008, after the capital markets close.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

The conference call will be hosted by senior management and will be held on Thursday, November 6, 2008 at 5:00 pm Eastern Time.

Investors may listen to the call by dialing (866) 550-6338 or (347) 284-6930 passcode 6760480, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing (888) 203-1112 or (719) 457-0820 confirmation code 6760480.

This conference call also will be webcast and may be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Human Pheromone Sciences, Inc. - Shareholder Update
2. The human brain minimizes energy expenditure and integrates gravity in to the action plan
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
5. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
6. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
8. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
9. Pigs bred with cystic fibrosis provide model to mimic human disease
10. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. ... and assays, and their applicability in drug safety assessment, for the industry as ...
(Date:1/17/2017)... COLUMBUS, Ohio , Jan. 17, 2017  On ... with the 35th Annual J.P. Morgan Healthcare Conference in ... Joseph D. Kittle, Jr. , spoke to pharmaceutical ... technology developed by ProclaRx to break down and destroy ... which protect bacteria and prevent antibiotics and the body,s ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... ... a CAGR of 16.83% during the period 2017-2021. The ... biopolymers market for 2017-2021. To calculate the market size, the report considers ... report also includes a a discussion of the key vendors operating in ...
Breaking Biology Technology:
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):